Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN006 Bivalent mRNA Vaccine in Healthy Adults
NCT06645665Phase 1Active, not recruiting
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IN006 in respiratory syncytial virus infection (RSV) (6 cohorts), sponsored by Shenzhen Shenxin Biotechnology Co., Ltd. Primary endpoints: Percentage of Participants With Solicited Local and Systemic Adverse Reactions at 14 days, Percentage of Participants With Unsolicited Adverse Events at 28 days and 6 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
IN006
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06645665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06645665.